Compliance and persistence of endocrine adjuvant breast cancer therapy

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 491-499

  Güth, Uwe ^a,b,c   Myrick, Mary Elizabeth ^a   Kilic, Nerbil ^a,b   Eppenberger Castori, Serenella ^d   Schmid, Seraina Margaretha ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UHB   (Switzerland)

^c CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Breast cancer; Compliance; Endocrine therapy; Persistence

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EXEMESTANE; FULVESTRANT; GONADORELIN DERIVATIVE; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL SPECIALIST; MOTIVATION; OVARIECTOMY; PARTIAL MASTECTOMY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SWITZERLAND; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 84856214788     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1801-y     Document Type: Article

References (29)

1. RT Chlebowski ML Geller 2006 Adherence to endocrine therapy for breast cancer Oncology 71 1-2 1 9 17344666 1:CAS:528:DC%2BD2sXktFemt7o%3D
2. P Hadji 2010 Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy Crit Rev Oncol Hematol 73 2 156 166 19299162 10.1016/j.critrevonc.2009.02.001
3. AH Partridge 2006 Non-adherence to endocrine therapy for breast cancer Ann Oncol 17 2 183 184 16428243 10.1093/annonc/mdj141 1:STN:280: DC%2BD28%2FjvVGktA%3D%3D (Pubitemid 43160103)
4. L Atkins L Fallowfield 2006 Intentional and non-intentional non-adherence to medication amongst breast cancer patients Eur J Cancer 42 14 2271 2276 16644208 10.1016/j.ejca.2006.03.004 (Pubitemid 44307611)
5. TI Barron R Connolly K Bennett J Feely MJ Kennedy 2007 Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 5 832 839 17243168 10.1002/cncr.22485 1:CAS:528:DC%2BD2sXjsVKns7s%3D (Pubitemid 46333524)
6. S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 2 322 328 11208822 1:CAS:528:DC%2BD3MXhtVektrk%3D (Pubitemid 32112842)
7. AK Fink J Gurwitz W Rakowski E Guadagnoli RA Silliman 2004 Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer J Clin Oncol 22 16 3309 3315 15310774 10.1200/JCO.2004.11.064 (Pubitemid 41103687)
8. U Guth DJ Huang A Schotzau R Zanetti-Dallenbach W Holzgreve J Bitzer E Wight 2008 Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer Br J Cancer 99 3 428 433 18665168 10.1038/sj.bjc.6604525 1:STN:280:DC%2BD1cvpvFaktA%3D%3D
9. DL Hershman LH Kushi T Shao D Buono A Kershenbaum WY Tsai L Fehrenbacher S Lin Gomez S Miles AI Neugut 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients J Clin Oncol 28 27 4120 4128 20585090 10.1200/JCO.2009.25.9655
10. TL Lash MP Fox JL Westrup AK Fink RA Silliman 2006 Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 2 215 220 16541307 10.1007/s10549-006-9193-0 (Pubitemid 44268270)
11. C Owusu DS Buist TS Field TL Lash SS Thwin AM Geiger VP Quinn F Frost M Prout MU Yood, et al. 2008 Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 4 549 555 18071188 10.1200/JCO.2006.10.1022 (Pubitemid 351264347)
12. AH Partridge A LaFountain E Mayer BS Taylor E Winer A Asnis-Alibozek 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 4 556 562 18180462 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D (Pubitemid 351264348)
13. AH Partridge PS Wang EP Winer J Avorn 2003 Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 4 602 606 12586795 10.1200/JCO.2003.07.071 1:CAS:528:DC%2BD2cXpsVGrtbs%3D (Pubitemid 46621892)
14. RA Silliman E Guadagnoli W Rakowski MB Landrum TL Lash R Wolf A Fink PA Ganz J Gurwitz C Borbas, et al. 2002 Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer J Clin Oncol 20 11 2680 2688 12039930 10.1200/JCO.2002.08.137 (Pubitemid 34575641)
15. DM Waterhouse KA Calzone C Mele DE Brenner 1993 Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring J Clin Oncol 11 6 1189 1197 8501505 1:STN:280:DyaK3s3nsVentQ%3D%3D (Pubitemid 23163362)
16. V Ziller M Kalder US Albert W Holzhauer M Ziller U Wagner P Hadji 2009 Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann Oncol 20 3 431 436 19150950 10.1093/annonc/mdn646 1:STN:280:DC%2BD1M7mvVynsA%3D%3D
17. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York
18. Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford
19. SE Andrade KH Kahler F Frech KA Chan 2006 Methods for evaluation of medication adherence and persistence using automated databases Pharmacoepidemiol Drug Saf 15 8 565 574 16514590 10.1002/pds.1230 discussion 575-567 (Pubitemid 44336271)
20. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 5 487 497 16079372 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D (Pubitemid 41127293)
21. AS Coates A Keshaviah B Thurlimann H Mouridsen L Mauriac JF Forbes R Paridaens M Castiglione-Gertsch RD Gelber M Colleoni, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 5 486 492 17200148 10.1200/JCO.2006.08.8617 1:CAS:528: DC%2BD2sXivF2mt7Y%3D (Pubitemid 350002953)
22. RC Coombes E Hall LJ Gibson R Paridaens J Jassem T Delozier SE Jones I Alvarez G Bertelli O Ortmann, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 11 1081 1092 15014181 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D (Pubitemid 38298988)
23. B Fisher J Costantino C Redmond R Poisson D Bowman J Couture NV Dimitrov N Wolmark DL Wickerham ER Fisher, et al. 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 8 479 484 2644532 10.1056/NEJM198902233200802 1:STN:280:DyaL1M7islChsw%3D%3D (Pubitemid 19062522)
24. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 1 45 53 18083636 10.1016/S1470-2045(07)70385-6
25. A Goldhirsch WC Wood RD Gelber AS Coates B Thurlimann HJ Senn 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 7 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
26. EA Grunfeld MS Hunter P Sikka S Mittal 2005 Adherence beliefs among breast cancer patients taking tamoxifen Patient Educ Couns 59 1 97 102 16198223 10.1016/j.pec.2004.10.005 (Pubitemid 41399883)
27. BE Compas MF Stoll AH Thomsen G Oppedisano JE Epping-Jordan DN Krag 1999 Adjustment to breast cancer: age-related differences in coping and emotional distress Breast Cancer Res Treat 54 3 195 203 10445418 10.1023/A:1006164928474 1:STN:280:DyaK1Mznt1Gqsg%3D%3D (Pubitemid 29322342)
28. PA Ganz CC Schag RL Heinrich 1985 The psychosocial impact of cancer on the elderly: a comparison with younger patients J Am Geriatr Soc 33 6 429 435 3998352 1:STN:280:DyaL2M3gvVykug%3D%3D (Pubitemid 15046023)
29. S Hong A Didwania O Olopade P Ganschow 2009 The expanding use of third-generation aromatase inhibitors: what the general internist needs to know J Gen Intern Med 24 Suppl 2 S383 S388 19838836 10.1007/s11606-009-1037-2